|
|
|
ABOUT US Building blocks for a better future
Abovchem was founded by MedChem and CMC veterans to serve the Drug Discovery community. Abovchem is a company of BirdoTech Pharma Group and the platform of Catalog Reagent and Compound Management. We focus on Building Blocks, Reference Compounds, and Custom Synthesis.
|
|
|---|
|
AC160248 -- Research Area: hERG, Fluorinated Piperidine |
|
|---|
|
The hERG channel is an important target not to hit in drug discovery. Fluorinated building blocks are often incorporated as a strategy to avoid such target. AbovChem has the fluorinated piperidine (AC160248) in stock in multi-kilo size.
In stock: US & China |
|
|---|
|
AC770364 -- Research Area: BCP, Photocatalyst |
|
|---|
|
Bicyclo[1.1.1]pentanes (BCPs) play an important role in drug design of sp3-rich structures. A research group of Oxford found a synthesis route for BCPs using organophotoredox catalyst (AC770364).
In stock: US & China |
|
|---|
|
AC774044 -- Research Area: TCNHPI |
|
|---|
|
TCNHPI(4, 5, 6, 7-tetrachloro-2-hydroxyisoindoline-1, 3-dione, 85342-65-0, AC774044) can be used in decarboxylative transformations with different coupling partners under a variety of conditions.
In stock: US & China |
|
|---|
|
AC504474 -- Research Area: TYK2 Inhibitor, Deucravacitinib |
|
|---|
|
The FDA and EMA have accepted the application for Deucravacitinib, a TYK2 inhibitor, to treat adults with moderate to severe plaque psoriasis. AC504474 is key intermediate of Deucravacitinib.
In stock: US & China |
|
|---|
|
AC130860 -- Research Area: Velexbru, BTK Inhibitor |
|
|---|
|
Velexbru (CAS: 1351636-18-4) is the world's first BTK inhibitor approved for the treatment of primary PCNSL. The building block that Abovchem can provide in the structure of Velexbru is AC130860.
In stock: US & China |
|
|---|
|
Pick up of the month
Methoxypyridine derivatives |
|
|---|
|
|
Your intro copy was exciting enough to keep your subscribers reading. Let's continue that trend here! |
|
|---|
|
|
| |
|
|
